What is the recommended management for colonic dysplasia?

Management of Colonic Dysplasia

For visible, clearly delineated colonic dysplasia without features of invasive cancer or submucosal fibrosis, endoscopic resection is the treatment of choice, while invisible multifocal or high-grade dysplasia requires surgical colectomy. 1

Initial Assessment and Classification

When colonic dysplasia is detected, immediately classify it as:

• Visible dysplasia: Polypoid (≥2.5 mm) or nonpolypoid (<2.5 mm) lesions
• Invisible dysplasia: Detected only on non-targeted biopsies

Document size, morphology, border clarity, ulceration presence, location, and whether it's within a colitis field. 1

Management Algorithm for Visible Dysplasia

Resectable Lesions

Proceed with endoscopic resection if the lesion has:

• Clear borders
• No features of submucosal invasion (no mucosal depression, irregular surface architecture, radiating folds, or failure to lift with submucosal injection)
• No stigmata of invasive cancer 1

Post-resection surveillance intervals:

• 3-6 months: High-grade dysplasia or incomplete resection
• 12 months: Lesions >1 cm with low-grade dysplasia
• 24 months: Lesions <1 cm or pedunculated with low-grade dysplasia 1

Unresectable Lesions

Refer for colectomy if:

• Incomplete resection after multiple attempts
• Features of invasive cancer
• Significant submucosal fibrosis
• Unresectable due to size or location 1

Important caveat: For large (>2 cm) or complex lesions (lateral spreading, irregular borders), consider endoscopic resection versus surgery based on local expertise and disease activity. Avoid excessive biopsies or unsuccessful resection attempts by inexperienced endoscopists—this causes submucosal scarring that makes future resection impossible. 1

Management Algorithm for Invisible Dysplasia

Step 1: Confirm and Re-evaluate

When invisible dysplasia is found on non-targeted biopsies:

1. Confirm histology with a second expert pathologist
2. Control inflammation before repeat examination
3. Perform high-definition dye spray chromoendoscopy (DCE) by an experienced endoscopist to unmask subtle lesions
4. Take extensive non-targeted biopsies (4 biopsies every 10 cm) in the area of prior dysplasia if no visible lesion is found 1

Step 2: Definitive Management Based on Findings

Surgical colectomy indicated for:

• Persistent high-grade invisible dysplasia
• Persistent multifocal invisible dysplasia (any grade) 1

Research confirms this approach: high-grade dysplasia carries a 29% risk of colorectal cancer in ulcerative colitis and 75% in Crohn's disease at colectomy. 2

Intensive surveillance (not surgery) for:

• Persistent unifocal low-grade invisible dysplasia
• No dysplasia found on repeat high-quality DCE 1

Surveillance intervals after unifocal low-grade invisible dysplasia:

• 3-6 months if prior high-grade or multifocal dysplasia
• 6-12 months if prior low-grade dysplasia
• Continue until 2 consecutive negative high-quality DCE exams 1

The rationale: modern data show considerably lower cancer risk with unifocal low-grade dysplasia due to improved endoscopic visualization, better inflammatory control, and improved bowel preparation. 1 Low-grade dysplasia carries only 4% cancer risk in ulcerative colitis and 14% in Crohn's disease. 2

Surveillance After No Dysplasia Found

Surveillance intervals based on risk stratification:

Annual (1 year):

• Moderate or severe inflammation (any extent)
• Primary sclerosing cholangitis
• First-degree relative with CRC age <50
• Dense pseudopolyposis 1

Every 2-3 years:

• Mild inflammation (any extent)
• Strong family history of CRC (but no first-degree relative <50)
• Features of prior severe colitis (moderate pseudopolyps, extensive scarring)
• History of invisible dysplasia or higher-risk visible dysplasia <5 years ago 1

Every 5 years:

• Continuous disease remission with mucosal healing
• Two consecutive exams without dysplasia
• Minimal historical colitis extent (ulcerative proctitis or <1/3 of colon in Crohn's disease)
• History of lower-risk visible dysplasia <5 years ago 1

Critical Technical Requirements

Optimize dysplasia detection by:

• Controlling inflammation before examination
• Using high-definition endoscopes
• Ensuring adequate bowel preparation
• Performing dye spray chromoendoscopy (or virtual chromoendoscopy with HD endoscopy) 1

Common pitfall: Using white light endoscopy alone without chromoendoscopy requires extensive non-targeted biopsies (4 biopsies every 10 cm), which significantly increases procedure time and may miss lesions. DCE with HD endoscopy eliminates this need unless there's a history of dysplasia or PSC. 1

Context-Specific Considerations

This guidance applies specifically to inflammatory bowel disease-associated dysplasia. The evidence provided focuses on IBD-colitis patients, where chronic inflammation drives a distinct carcinogenesis pathway characterized by field cancerization and multifocality. 3

For sporadic adenomas in non-IBD patients, standard polypectomy with routine surveillance intervals applies—do not conflate these pathways. 4

Multidisciplinary discussion is warranted when:

• Uncertainty exists about resectability
• Complex lesions require advanced techniques (endoscopic mucosal resection or endoscopic submucosal dissection)
• Risk-benefit assessment is needed for unifocal invisible dysplasia management 1